It was a pleasure catching up with Gilead Sciences‘ PURPOSE 1 protocol leadership following my presentation at the recently concluded CROI 2025 meeting in SanFrancisco.
Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
